Abstract
Triiodobenzoic acid (TIBA) represents the core structure of most clinically used contrast agents for computed tomography and other X-ray procedures. To construct an intracellular radiopaque contrast agent, TIBA was coupled to various different positively and negatively charged fluorescein iothiocyanate (FITC)-labelled peptides. TIBA coupled to the SV40 T Antigen nuclear localization sequence (NLS) stained 80% of human glioma cells and caused cell death. This occurred with C- or N-terminal binding of TIBA and with the correct or mutant NLS. No cell death and only small numbers of stained cells (below 3 %) were observed after incubation with NLS conjugates lacking TIBA or after incubation with TIBA-conjugates containing a negatively charged polyglutamic acid stretch. TIBA-conjugates containing the Antennapedia-derived cell-penetrating peptide penetratin were only nuclearly taken up when TIBA and FITC were coupled to lysines outside the 16-amino acid peptide sequence. The study shows that intracellular TIBA may have potential as a chemotherapeutic agent rather than a contrast agent.
Keywords: 2,3,5-triiodobenzoic acid, NLS, cell nucleus, FITC, transmembrane transport, glioma, penetratin, polyglutamic acid
Medicinal Chemistry
Title: Cell Nucleus Directed 2,3,5-triiodobenzoic Acid Conjugates
Volume: 5 Issue: 4
Author(s): Alexander Sturzu, Ulrich Vogel, Alireza Gharabaghi, Alexander Beck, Hubert Kalbacher, Hartmut Echner and Stefan Heckl
Affiliation:
Keywords: 2,3,5-triiodobenzoic acid, NLS, cell nucleus, FITC, transmembrane transport, glioma, penetratin, polyglutamic acid
Abstract: Triiodobenzoic acid (TIBA) represents the core structure of most clinically used contrast agents for computed tomography and other X-ray procedures. To construct an intracellular radiopaque contrast agent, TIBA was coupled to various different positively and negatively charged fluorescein iothiocyanate (FITC)-labelled peptides. TIBA coupled to the SV40 T Antigen nuclear localization sequence (NLS) stained 80% of human glioma cells and caused cell death. This occurred with C- or N-terminal binding of TIBA and with the correct or mutant NLS. No cell death and only small numbers of stained cells (below 3 %) were observed after incubation with NLS conjugates lacking TIBA or after incubation with TIBA-conjugates containing a negatively charged polyglutamic acid stretch. TIBA-conjugates containing the Antennapedia-derived cell-penetrating peptide penetratin were only nuclearly taken up when TIBA and FITC were coupled to lysines outside the 16-amino acid peptide sequence. The study shows that intracellular TIBA may have potential as a chemotherapeutic agent rather than a contrast agent.
Export Options
About this article
Cite this article as:
Sturzu Alexander, Vogel Ulrich, Gharabaghi Alireza, Beck Alexander, Kalbacher Hubert, Echner Hartmut and Heckl Stefan, Cell Nucleus Directed 2,3,5-triiodobenzoic Acid Conjugates, Medicinal Chemistry 2009; 5 (4) . https://dx.doi.org/10.2174/157340609788681485
DOI https://dx.doi.org/10.2174/157340609788681485 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Targeting with RGD Peptide Ligands-Design of New Molecular Conjugates for Imaging and Therapy of Cancers
Anti-Cancer Agents in Medicinal Chemistry The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology The Ever Changing Treatments for Tumors of the Central Nervous System
Current Cancer Therapy Reviews Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents
Current Medicinal Chemistry ADP-Ribosyl Cyclase as a Therapeutic Target for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry Research Progress on the Antitumor Effects of Rhein: Literature Review
Anti-Cancer Agents in Medicinal Chemistry Deglucohellebrin: A Potent Agent for Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile
Current Pharmaceutical Design Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Targeted Nanosystems for Cancer Therapy
Current Cancer Therapy Reviews Microarray Technologies for Intracellular Kinome Analysis
Current Medicinal Chemistry Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Morphology of C6 Glioma Cells on a Water-Repellent Fractal Alkyl Ketene Dimer Surface
Current Nanoscience Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Chemotherapy and Target Therapy in the Management of Adult High- Grade Gliomas
Current Cancer Drug Targets Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology